| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
-- Announces PANORAMA, an OnKure-sponsored, large-scale, multiregional registry designed to characterize the natural disease course and treatment patterns of people living with vascular anomalies |
| 04 Nov 2026 | 10-Q |
| 07 Oct 2026 | SCHEDULE 13G |
| 23 Sep 2026 |
Form 4: Saccomano Nicholas A, Director
Sold 87 shares ($259) |
| 23 Sep 2026 |
Form 4: Leverone Jason A., Chief Financial Officer
Sold 302 shares ($898) |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 |
Form 4/A: Manke Isaac, Director
Holds 15,300 Stock Option (right to buy) (exercise price $18.20, expires Oct 3, 2034) |
| 13 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On August 7, 2026 (the “Effective Date”), the Board of Directors (the “Board”) of OnKure Therapeutics, Inc. (the “Company”) approved an option repricing. The repricing generally applied to all outstanding and unexercised stock options to... |
| 11 Aug 2026 |
Form 4: Mathers Edward T, Director
Granted 22,350 Stock Option (right to buy) |
| 11 Aug 2026 |
Form 4: Ratcliffe Liam, Director
Granted 22,350 Stock Option (right to buy) |
| 11 Aug 2026 |
Form 4: Phillips Andrew John, Director
Granted 22,350 Stock Option (right to buy) |
| 11 Aug 2026 |
Form 4: Manke Isaac, Director
Granted 315,300 Stock Option (right to buy) · Disposed of 15,300 Stock Option (right to buy) (Disposition to Issuer) |
| 11 Aug 2026 |
Form 4: Jansen Valerie Malyvanh, Director
Granted 22,350 Stock Option (right to buy) |
| 11 Aug 2026 |
Form 4: Grey Michael G, Director
Granted 22,350 Stock Option (right to buy) |
| 11 Aug 2026 |
Form 4: Carruthers R Michael, Director
Granted 22,350 Stock Option (right to buy) |
| 11 Aug 2026 |
Form 4: Saccomano Nicholas A, Director
Granted 721,423 Employee Stock Option (right to buy) · Disposed of 571,423 Employee Stock Option (right to buy) (Disposition to Issuer) |
| 11 Aug 2026 |
Form 4: Leverone Jason A., Chief Financial Officer
Granted 185,933 Employee Stock Option (right to buy) · Disposed of 5,781 Employee Stock Option (right to buy (Disposition to Issuer) · Granted 5,781 Employee Stock Option (right to buy · 1 more |
| 11 Aug 2026 |
Form 4: Hartley Dylan, Chief Scientific Officer
Granted 187,603 Employee Stock Option (right to buy) · Disposed of 137,603 Employee Stock Option (right to buy) (Disposition to Issuer) |
Loading...